Boceprevir

Janessa Smith, Pharm.D. BCPS, Paul A. Pham, PharmD
Boceprevir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Boceprevir is indicated for the treatment of HCV (genotype1, used in combination with peg-INF + ribavirin) in adult patients with compensated liver disease, including cirrhosis.
    • Boceprevir may be used in either treatment-naïve patients or those who have failed previously interferon/ribavirin therapy.

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: March 4, 2018

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Boceprevir ID - 540605 A1 - Pham,Paul,PharmD AU - Smith,Janessa,Pharm.D. BCPS Y1 - 2018/03/04/ BT - Johns Hopkins ABX Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540605/all/Boceprevir PB - The Johns Hopkins University DB - Pediatrics Central DP - Unbound Medicine ER -